Worldwide, 150 million people are estimated to be infected with HCV, three-quarters of whom live in middle-income countries and represent the poorest and most marginalised populations. 90% of new HCV infections are in people who inject drugs. The consequences of chronic HCV infection include cirrhosis, end-stage liver disease, and cancer. Yet stigma, poverty, weak health systems, and high drug costs remain barriers to effective diagnosis and treatment.
Read Full Article »
